Clinical Trials Logo

Uterine Carcinosarcoma clinical trials

View clinical trials related to Uterine Carcinosarcoma.

Filter by:

NCT ID: NCT00114218 Completed - Clinical trials for Uterine Carcinosarcoma

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent or persistent uterine cancer. Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

NCT ID: NCT00075400 Completed - Clinical trials for Uterine Carcinosarcoma

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00025506 Completed - Clinical trials for Uterine Carcinosarcoma

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Start date: September 2001
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite treatment. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.